The Advancing Education on Biosimilars Act of 2021 increases awareness and adoption of biosimilar drugs, directly benefiting biosimilar manufacturers and increasing competition for branded biologic drug companies. This legislation expands the market for biosimilars and drives down healthcare costs.
Impact: 6/10S164Congressional Bill